Ajanta Pharma Ltd

Meeting Details

• Date and time: 30 October 2026, 16:00–17:00 IST.
• Type and mode: group, virtual earnings conference call.
• Event/organiser: Earnings Conference Call organised by Ajanta Pharma.
• Purpose: discuss Q2 FY2027 unaudited results and take questions.
• Key participants: company leadership team.
• Recording availability: transcript will be available on the Ajanta Pharma website.
• Playback: audio playback available 120 minutes after end on the company website.

Meeting Details

• Date: 30 October 2026; time and venue not disclosed.

Key Agenda Items

• Consider and approve unaudited consolidated and standalone financial results for Q2 and H1 ended 30 September 2026.

Other Notes

• No additional material notes disclosed.

Key ESG highlights

• Renewable energy capacity reached 16.6 MW, supplying about one-third of total energy needs.
• Scope 1 emissions fell to 3,363.93 tCO2e from 6,392; Scope 2 dropped to 46,575.74 tCO2e.
• Targets: Scope 1 -70% by 2027; Scope 2 -50% by 2027; Scope 3 -15% by 2032.
• Renewable energy contributed 86,539.92 GJ; total energy 354,866.99 GJ; energy intensity 0.00000651 GJ per turnover.
• Water withdrawal 533,648.1 KL; 1.5 lakh KL conservation potential in Marathwada; Zero Liquid Discharge.
• Total waste 3,466.42 MT; 2,888 MT recovered; 578.42 MT disposed; 99% hazardous waste co-processed.
• 11,800 trees planted in FY2026; target 20,000 by FY2027; sites outside protected areas.
• Zero fatalities and zero LTIs across 10,404 employees and 2,802 workers.
• Board comprises eight directors; 50% independent; two women independent; ESG governance via Sustainability Council and CSR Committee.
• Health initiatives reached 210,725 beneficiaries; education 135,383; sports 16,982; cataract surgeries 80,103.

Release of pledge on promoter shares

• Pledge release on 21-Sep-26 reduced encumbered promoter shares from 1,17,40,571 (9.40%).
• Post-21-Sep-26 encumbered shares: 1,16,85,071 (9.35%).
• Pledge release on 22-Sep-26 reduced encumbrance to 1,16,66,553 (9.34%).
• Pledge release on 23-Sep-26 reduced encumbrance to 1,16,42,386 (9.32%).
• Lender: Aditya Birla Capital Ltd; end-use: loan repayment.
• Promoter: Aayush M Agrawal, trustee Aayush Agrawal Trust.
• Initial promoter encumbrance: 1,41,12,924 promoter holding (11.29%).
• Pre-release encumbrance by promoter group: 1,17,40,571 (9.40%).
• Final encumbered holding after all releases: 1,16,42,386 (9.32%).

Ajanta Pharma Ltd — Trading Window closed from 01 October 2026 till 48 hours after declaration of Financial Results for the second quarter and half year ended 30 September 2026

Encumbrance release

• Target company: Ajanta Pharma Limited.
• Event: Release of pledge on promoter shares.
• Shares released: 17,36,353.
• Promoter: Aayush Agrawal, trustee Aayush Agrawal Trust.
• Reason: loan repayment.
• Promoter holding before release: 1,41,12,924 shares (11.29%).
• Promoter holding after release: 1,34,76,924 shares (10.79%).

Meeting Details

• 16 September 2026: Jefferies India Forum; one-on-one; Oberoi, New Delhi.
• 28 September 2026: PL Capital Mid & Small Cap Conference 2026; Trident, BKC.

Participants

• No specific management participants named for the meetings.

Purpose

• Analyst/Institutional investor meetings; discussions based on published information.